Cargando…
SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses
BACKGROUND: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 110 million individuals and led to 2.5 million deaths worldwide. As more individuals are vaccinated, the clinical performance and utility of SARS-CoV-2 serology platforms needs to be evaluated. METHODS: Th...
Autores principales: | Suhandynata, Raymond T, Bevins, Nicholas J, Tran, Jenny T, Huang, Deli, Hoffman, Melissa A, Lund, Kyle, Kelner, Michael J, McLawhon, Ronald W, Gonias, Steven L, Nemazee, David, Fitzgerald, Robert L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409063/ https://www.ncbi.nlm.nih.gov/pubmed/34170314 http://dx.doi.org/10.1093/jalm/jfab080 |
Ejemplares similares
-
SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses
por: Suhandynata, Raymond T., et al.
Publicado: (2021) -
Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens
por: Lund, Kyle, et al.
Publicado: (2023) -
Healthcare worker seroconversion for SARS-CoV-2 at two large health systems in San Diego
por: Nicholson, Laura, et al.
Publicado: (2021) -
Evaluation of six commercial kits for the serological diagnosis of Mediterranean visceral leishmaniasis
por: Lévêque, Maude F., et al.
Publicado: (2020) -
Validation of a commercially available SARS-CoV-2 serological immunoassay
por: Meyer, B., et al.
Publicado: (2020)